Cell Biology: State of the Art and Perspectives in Italy 2025

A special issue of Cells (ISSN 2073-4409).

Deadline for manuscript submissions: 30 September 2025 | Viewed by 853

Special Issue Editor


E-Mail Website
Guest Editor
Department of Precision Medicine, University of Campania Luigi Vanvitelli, 80138 Napoli, Italy
Interests: programmed cell death; apoptosis; leukaemia; epigenetic; acetylation; sirtuins
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are thrilled to announce the third edition of the Special Issue "Cell Biology: State of the Art and Perspectives in Italy 2025". Following the success of the previous two editions, this new installment continues to celebrate the remarkable advancements and contributions of the Italian scientific community to the field of cell biology.

This Special Issue provides a dynamic platform that highlights groundbreaking research, fosters interdisciplinary collaboration, and inspires innovation within the field. By showcasing recent discoveries, technologies, and perspectives, we aim to elucidate the intricate mechanisms of cellular life and their far-reaching implications.

In this edition, we look forward to receiving contributions that explore both fundamental and applied aspects of cell biology. The scope of this Special Issue includes, but is not limited to, the following topics:

  • Cell structure: organelles, cytoskeleton, cell membranes, flagella, etc.;
  • Cell physiology: metabolism, protein synthesis, DNA repair, intracellular signaling, transport mechanisms, etc.;
  • Cellular processes: autophagy, apoptosis, motility, aging, growth, and differentiation;
  • Hematopoiesis and stem cells, including cancer stem cells and CAR-T cell research;
  • Genetic disorders and their cellular basis;
  • Advanced cell techniques: tissue culture, cell isolation, ICC, ISH, transfection, optogenetics, etc.

This Special Issue seeks to emphasize the interdisciplinary and translational nature of cell biology, highlighting its critical role in addressing global challenges and advancing knowledge in the life sciences. We welcome the submission of original research articles, reviews, and communications that reflect the diversity, creativity, and excellence of Italian cell biology research in 2025.

We look forward to receiving your contributions and to building upon the strong foundation established in the earlier editions. Together, let us continue to push the boundaries of our understanding of cell biology and inspire impactful scientific collaborations.

Dr. Vincenzo Carafa
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cell biology
  • physiology
  • molecular biology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

47 pages, 1310 KiB  
Review
Impact of High-Efficacy Therapies for Multiple Sclerosis on B Cells
by Federica Galota, Simone Marcheselli, Sara De Biasi, Lara Gibellini, Francesca Vitetta, Alessia Fiore, Krzysztof Smolik, Giulia De Napoli, Martina Cardi, Andrea Cossarizza and Diana Ferraro
Cells 2025, 14(8), 606; https://doi.org/10.3390/cells14080606 - 17 Apr 2025
Viewed by 616
Abstract
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative autoimmune disorder of the central nervous system characterized by demyelination and neurodegeneration. Traditionally considered a T-cell-mediated disease, the crucial role of B lymphocytes in its pathogenesis, through different mechanisms contributing to inflammation and autoreactivity, [...] Read more.
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative autoimmune disorder of the central nervous system characterized by demyelination and neurodegeneration. Traditionally considered a T-cell-mediated disease, the crucial role of B lymphocytes in its pathogenesis, through different mechanisms contributing to inflammation and autoreactivity, is increasingly recognized. The risk of long-term disability in MS patients can be reduced by an early treatment initiation, in particular with high-efficacy therapies. The aim of this review is to provide an overview of the mechanisms of action of high-efficacy therapies for MS, with a focus on their impact on B cells and how this contributes to the drugs’ efficacy and safety profiles. Anti-CD20 monoclonal antibodies, Alemtuzumab, Cladribine and sequestering therapies encompassing Natalizumab and S1P receptors modulators will be discussed and emerging therapies, including Bruton’s Tyrosine Kinase inhibitors, will be presented. Full article
(This article belongs to the Special Issue Cell Biology: State of the Art and Perspectives in Italy 2025)
Show Figures

Figure 1

Back to TopTop